Clinical Trials Directory

Trials / Completed

CompletedNCT03269721

COPD-Related Physiology and the Brain

Determinants of Altered Brain Structure and Function in Smokers With COPD-Related Lung Pathophysiology

Status
Completed
Phase
Study type
Observational
Enrollment
170 (actual)
Sponsor
Karin Hoth · Academic / Other
Sex
All
Age
30 Years – 85 Years
Healthy volunteers
Accepted

Summary

COPD is the third leading cause of combined morbidity, disability, and mortality in the United States and is often associated with cognitive impairment. The goal of the proposed project is to examine novel pulmonary and vascular physiological mechanisms that contribute to structural brain abnormalities and cognitive dysfunction early in the course of COPD. The project will generate information to ultimately inform the development of interventions to delay or prevent cognitive dysfunction.

Detailed description

Chronic Obstructive Pulmonary Disease (COPD) is the 3rd leading cause of morbidity and mortality in the US with increasing prevalence in older adults. The impact of COPD on the brain is an area of expanding research interest. A staggering 40-60% of patients with COPD have cognitive impairments including deficits in executive functioning (e.g., decision making), processing speed, and memory. Intact cognition is critical for independently managing daily tasks (e.g., medication and money management). Since there are currently no treatments to fully reverse cognitive impairment once it is present, preventing and delaying onset is essential. Given the high prevalence of COPD, understanding how COPD confers an increased risk for cognitive impairment should be a top public health priority. There is an urgent need to identify potentially modifiable physiological characteristics of individuals with early COPD-related pathophysiology who are at risk of developing brain abnormalities. The earliest changes that occur in COPD are driven by an enhanced chronic inflammatory response that includes small airway disease in the lung and vascular abnormalities. COPD-related lung pathophysiology can be measured continuously and is separable from amount of smoking. These physiological changes are often present in individuals who do not meet traditional criteria for COPD diagnosis and have not yet manifested significant clinical symptoms. We propose that chronic smokers who are susceptible to COPD and show evidence of COPD-related lung pathophysiology on lung CT also experience vascular dysfunction (particularly central artery stiffness) that contributes to structural brain abnormalities and cognitive impairment. The proposed project will: 1) model the effects of novel physiological mechanisms on the brain in COPD, 2) focus on changes in brain structure and function early in the development of COPD by including smokers who have evidence of early COPD-related lung pathophysiology but do not meet traditional criteria for COPD, and 3) utilize advanced technology to assess the lung (lung CT) and brain (MRI). We will recruit participants with existing lung CT from ongoing NIH projects to complete pulmonary and vascular measures, cognitive assessment, and brain MRI. The project is highly multidisciplinary and leverages unique resources at the University of Iowa including the Institute for Clinical and Translational Science, the Translational Human Vascular Physiology Lab, the Iowa Neuroimaging Consortium, and the Iowa Comprehensive Lung Imaging Center.

Conditions

Interventions

TypeNameDescription
BEHAVIORALNeuropsychological AssessmentAssessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
PROCEDURESpirometryPre and post bronchodilator spirometry will be administered according to the American Thoracic Society (ATS) guidelines.
PROCEDUREArterial Blood GasRadial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
PROCEDUREDiffusion Capacity of the Lung for Carbon MonoxideFor measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
DIAGNOSTIC_TEST6 Minute Walk TestDistance walked in 6 minutes will be the primary outcome.
PROCEDURESystemic Vascular MeasuresCarotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
BIOLOGICALBlood BiomarkersHigh sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
BEHAVIORALSymptom Questionnaire MeasuresM.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
PROCEDUREBrain MRIPrimary neuroimaging outcomes of interest are white matter structural integrity

Timeline

Start date
2017-05-01
Primary completion
2025-04-30
Completion
2025-04-30
First posted
2017-09-01
Last updated
2025-12-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03269721. Inclusion in this directory is not an endorsement.